Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 4
2005 7
2006 9
2007 6
2008 7
2009 6
2010 12
2011 14
2012 8
2013 4
2014 5
2015 4
2016 7
2017 14
2018 13
2019 17
2020 13
2021 10
2022 10
2023 6
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Results by year

Filters applied: . Clear all
Page 1
Relapsed and refractory multiple myeloma: A systematic review and network meta-analysis of the efficacy of novel therapies.
Minakata D, Fujiwara SI, Yokoyama D, Noguchi A, Aoe S, Oyama T, Koyama S, Murahashi R, Nakashima H, Hyodo K, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Mashima K, Umino K, Morita K, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Kanda Y. Minakata D, et al. Among authors: sato k. Br J Haematol. 2023 Mar;200(6):694-703. doi: 10.1111/bjh.18654. Epub 2023 Jan 20. Br J Haematol. 2023. PMID: 36661264 Review.
Risk factors for high-dose methotrexate-induced nephrotoxicity.
Kawaguchi S, Fujiwara SI, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Toda Y, Ito S, Ban T, Nagayama T, Umino K, Minakata D, Nakano H, Yamasaki R, Ashizawa M, Yamamoto C, Hatano K, Sato K, Oh I, Ohmine K, Kanda Y. Kawaguchi S, et al. Among authors: sato k. Int J Hematol. 2021 Jul;114(1):79-84. doi: 10.1007/s12185-021-03132-8. Epub 2021 Mar 20. Int J Hematol. 2021. PMID: 33743109
Daratumumab in first-line therapy is cost-effective in transplant-eligible patients with newly diagnosed myeloma.
Yamamoto C, Minakata D, Koyama S, Sekiguchi K, Fukui Y, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Kawaguchi SI, Toda Y, Ito S, Nagayama T, Umino K, Nakano H, Morita K, Yamasaki R, Ashizawa M, Ueda M, Hatano K, Sato K, Ohmine K, Fujiwara SI, Kanda Y. Yamamoto C, et al. Among authors: sato k. Blood. 2022 Aug 11;140(6):594-607. doi: 10.1182/blood.2021015220. Blood. 2022. PMID: 35580269 Free PMC article.
[Infusion reactions].
Sato K, Kohgo Y. Sato K, et al. Gan To Kagaku Ryoho. 2008 Oct;35(10):1671-4. Gan To Kagaku Ryoho. 2008. PMID: 18931569 Japanese.
Antibody-mediated pathogenesis of chronic GVHD through DBY/HLA class II complexes and induction of a GVL effect.
Umino K, Morita K, Ikeda T, Kawaguchi SI, Nagayama T, Ito S, Minakata D, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Fujiwara SI, Kimura SI, Kako S, Doki N, Ozawa Y, Mori Y, Eto T, Hiramoto N, Nakamae H, Kanda J, Ichinohe T, Atsuta Y, Nakasone H, Morishima S, Kanda Y. Umino K, et al. Among authors: sato k. Blood. 2023 Sep 14;142(11):1008-1021. doi: 10.1182/blood.2023019799. Blood. 2023. PMID: 37363859
Mechanisms of immunomodulation by mesenchymal stem cells.
Ozaki K, Sato K, Oh I, Meguro A, Tatara R, Muroi K, Ozawa K. Ozaki K, et al. Among authors: sato k. Int J Hematol. 2007 Jul;86(1):5-7. doi: 10.1532/IJH97.07003. Int J Hematol. 2007. PMID: 17675259 Review.
Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple Myeloma.
Yamamoto C, Minakata D, Yokoyama D, Furuki S, Noguchi A, Koyama S, Oyama T, Murahashi R, Nakashima H, Ikeda T, Kawaguchi SI, Hyodo K, Toda Y, Ito S, Nagayama T, Umino K, Morita K, Ashizawa M, Ueda M, Hatano K, Sato K, Ohmine K, Fujiwara SI, Kanda Y. Yamamoto C, et al. Among authors: sato k. Transplant Cell Ther. 2024 Jan;30(1):118.e1-118.e15. doi: 10.1016/j.jtct.2023.10.001. Epub 2023 Oct 5. Transplant Cell Ther. 2024. PMID: 37802181
Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement.
Umino K, Fujiwara SI, Ikeda T, Toda Y, Ito S, Mashima K, Minakata D, Nakano H, Yamasaki R, Kawasaki Y, Sugimoto M, Yamamoto C, Ashizawa M, Hatano K, Sato K, Oh I, Ohmine K, Muroi K, Kanda Y. Umino K, et al. Among authors: sato k. Hematology. 2018 Sep;23(8):470-477. doi: 10.1080/10245332.2018.1446279. Epub 2018 Feb 28. Hematology. 2018. PMID: 29486661 Review.
Urine Xanthine Crystals in Hematologic Malignancies with Tumor Lysis Syndrome.
Ito S, Fujiwara SI, Yoshizawa T, Hayatsu K, Sekiguchi K, Murahashi R, Nakashima H, Matsuoka S, Ikeda T, Toda Y, Kawaguchi S, Nagayama T, Umino K, Minakata D, Nakano H, Morita K, Yamasaki R, Ashizawa M, Yamamoto C, Hatano K, Sato K, Ohmine K, Kanda Y. Ito S, et al. Among authors: sato k. Intern Med. 2022 Nov 1;61(21):3271-3275. doi: 10.2169/internalmedicine.9332-22. Epub 2022 Apr 2. Intern Med. 2022. PMID: 35370238 Free PMC article.
153 results